MSCO | QNA

Thank your for your time!

Q1. What are the recommendations for flexible care given by the NHS under COVID-19?

A: Transition outpatient care to care at home wherever possible 0%

B: Switch from infusional therapy to oral oncolytics if equivalent formulation is available 0%

C: Switching intravenous treatments to subcutaneous or oral alternatives where this would be beneficial 0%

D: All of the above 0%

NHS has recommended that try to deliver systemic anticancer treatment in different and less immunosuppressive regimens, different locations or via another route of administration where possible.

(https://www.nice.org.uk/guidance/ng161)

Q2. Which of the following is not an advantage of flexible care for patients, caregivers and HCPs?

A: Reduces Burden on Hospitals 0%

B: Offer better QoL for patients and caregivers 0%

C: Increase response rate for treatment 0%

D: Provides convenience access to cancer care 0%

Referring to speaker slide at time: 09:2

Q3. What are the requirements for implementing flexible care?

A: Identification of patients and staff 0%

B: Safety and governance 0%

C: Linking oncology centres with local healthcare 0%

D: All of the above 0%

Referring to speaker slide at time: 11:25

Q4. Why subcutaneous (SC) formulations are well suited for oncology flexible care initiatives?

A: SC formulations are quicker to administer and more convenient for patients , carers and HCPs vs. IV formulations 0%

B: Fixed-dose formulations help reduce dosing errors and simplify drug preparation and administration 0%

C: SC formulations have shown no new safety signals vs. IV formulations 0%

D: All of the above 0%

Referring to speaker slide at time: 16:38

Q5. What are the main reasons for SC preference in PreHER study?

A: Time saving 0%

B: Less pain/ discomfort/ inconvenience for patients 0%

C: Less alopecia 0%

D: A & B 0%

The preHER study has found that the two main reasons that patients gave for preferring s.c. when asked in an open-ended question were that it saved time and that it resulted in less pain/discomfort/side effects

(Ann Oncol 2014 Oct;25(10):1979-1987)